A long-acting Factor VIII replacement therapy for haemophilia A from Sobi and Sanofi has been recommended for use by the NHS ...

Pfizer has ended the global commercialisation of its haemophilia B (factor IX deficiency) gene therapy Beqvez, citing soft ...

NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in ...

Dosing is based on the person’s weight and the treatment at list price would cost around £510,000 per year for an adult ...

Haemophilia, a rare blood disorder affecting clotting, is one such condition that can manifest early in life. It’s essential to understand haemophilia. Simply put, haemophilia is a condition ...

Haemophilia, a rare blood disorder affecting clotting, is one such condition that can manifest early in life. It’s a ...

HIBISCUS phase 2 data evaluating the safety profile and efficacy of etavopivat in adult and adolescent patients with sickle cell disease FRONTIER4 interim phase 3 results evaluating safety profile and ...

Alison Dawson-Meadows, who works for United Lincolnshire Teaching Hospitals NHS Trust, was given the honour by The Haemophilia Society. Ms Dawson-Meadows is part of a team that supports 600 ...

Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low demand and interest. A Pfizer spokesperson told Pharmaceutical Technology in ...

Sobi’s Sanofi-partnered efanesoctocog alfa has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA ...

Suggested remit: To appraise the clinical and cost effectiveness of fidanacogene elaparvovec within its anticipated marketing authorisation for treating moderately severe to severe haemophilia B. The ...